Polaryx Therapeutics (PLYX) vs Stablecoin Development (SDEV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Stablecoin Development is the larger company by market cap ($103.0 million vs $99.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PLYX | SDEV |
|---|---|---|
| Share price | $2.00 | $1.99 |
| Market cap | $99.69M | $102.99M |
| 1-day change | -4.31% | -28.42% |
| YTD return | — | -92.94% |
| 1-year return | — | -66.83% |
| 5-year return | — | -99.94% |
| EPS (TTM) | $-0.14 | $-21.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $48.91 | $99.75 |
| 52-week low | $1.85 | $0.78 |
| Distance from 52-week high | -95.91% | -98.01% |
| Analyst consensus | none | — |
| Avg. price target upside | +275.00% | — |
| Average volume | 76.41K | 11.74M |
| Shares outstanding | 49.85M | 51.75M |
| Employees | 2 | 2 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Polaryx Therapeutics in Healthcare and Stablecoin Development in Health Care.
About Polaryx Therapeutics
PLYX stock →Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.
Healthcare · Biotechnology · 2 employees
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
PLYX vs SDEV FAQ
Which is bigger, Polaryx Therapeutics or Stablecoin Development?
Stablecoin Development (SDEV) is larger, with a market capitalization of $102.99M compared with $99.69M for Polaryx Therapeutics (PLYX).
Are Polaryx Therapeutics and Stablecoin Development in the same industry?
No. Polaryx Therapeutics is in the Healthcare sector, while Stablecoin Development is in Health Care.